Komen Commits Nearly $58 Million for Research in 2011

Susan G. Komen for the Cure commits nearly $58 million in 2011 to tackle the toughest issues with new, innovative approaches to breast cancer research.

 

As the global leader in the breast cancer movement, Komen's latest research grants focus on the development of  breast cancer vaccine, creating more effective therapies and reducing disparities in treatments for African Americans and other ethnic groups. 


Developing genetic interventions that target the immune system and creating personalized cancer vaccines are just two of more than 80 innovative research grants being funded this year by Susan G. Komen for the Cure®. The world's largest breast cancer organization announced it will fund $55 million toward research grants at 56 institutions across the United States and internationally in 2011.

 

Among those institutions are five in the Komen Philadelphia Affiliate service area:

  • Lankenau Institute for Medical Research
  • Thomas Jefferson University
  • University of Pennsylvania (2 grants)
  • Wistar Institute

"Our goal at Komen is to fund research with the greatest potential to make a difference and save lives in the shortest period of time. That means putting our dollars toward cutting-edge research that is high-risk, with potentially huge rewards," said Ambassador Nancy G. Brinker, founder and CEO of Komen for the Cure.  

 

"We thank and congratulate the doctors in our community for demonstrating the integrity, ingenuity and dedication to the cures for breast cancer that merited these grants," said Elaine I. Grobman, Executive Director of the Komen Philadelphia Affiliate. "These grant awards are another powerful way Susan G. Komen for the Cure connects local communities with global resources to bring us closer to the reality of life without breast cancer."

 

Click here for additional details and the complete list of grantees and funded programs